A Multicenter, Randomized, Double-Blind, Crossover, Phase 2 Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
Latest Information Update: 28 Aug 2024
At a glance
- Drugs ST-1891 (Primary) ; Levothyroxine sodium
- Indications Hypothyroidism
- Focus Therapeutic Use
- Sponsors Sention
Most Recent Events
- 26 Aug 2024 Status changed from active, no longer recruiting to completed.
- 28 Apr 2023 The study protocol was amended with change is time frame of primary and secondary endpoint from Week 26 to Week 52.
- 28 Apr 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2023.